NCT07582185Not yet recruitingPhase 4
Tdose Binding and Tocilizumab
Non-inferiority Study of TOCILIZUMAB Administered at Standardized, Fixed-interval Doses Versus Weight-based Dosing in Patients With Low-activity or Clinically Remitted Rheumatoid Arthritis.
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
The investigators aim to evaluate the non-inferiority of administering tocilizumab at a fixed dose versus a weight-based dose in patients with rheumatoid arthritis in remission or with low clinical activity, after 3 months of treatment, as part of a two-center randomized trial.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 122 (estimated)
- First submitted
- 6 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07582185
- EU CT number
- 2025-522319-41-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 122
- From 1 Jun 2026 to the primary completion date, 30 Sept 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis
- Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg
Other illness
- Diverticulitis or history of digestive perforation
Other
- Active neoplasia
Who the study is looking for
- Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria
- Rheumatoid Arthritis in low activity or remission according to DAS28
- Patient to receive a TOCILIZUMAB infusion 8mg/kg
- Patient with failure of treatment with cDMARDs or bDMARDs
- Concomitant treatment(s) for rheumatism allowed: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroid therapy (\< 10 mg/day of prednisone equivalent)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Saint Joseph Coordinator of this site? Confirm its status | Marseille | France | Not yet recruiting |
| Centre Hospitalier Universitaire de Nice Coordinator of this site? Confirm its status | Nice | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.